PBR Nachrichten

 

The designation recognises the potential of RTx-015 to address significant unmet medical needs in patients with severe retinal degeneration. It advances the therapy's regulatory support following a regenerative The post Ray Therapeutics receives EMA PRIME status for gene therapy appeared first on Pharmaceutical Business review....

On a non-GAAP basis, net income rose 12% to $1.04bn from $928m. GAAP diluted earnings per share (EPS) stood at $6.75 while non-GAAP diluted EPS grew 15% year-on-year The post Regeneron Q1 2026 net income falls 10% to $727m appeared first on Pharmaceutical Business review....

The initiative aligns with China's and the United Arab Emirates' (UAE) broader strategic objectives to enhance healthcare and the life sciences industry. The MoU was signed by Arcera The post Arcera and Fosun sign MoU for neuroscience innovation appeared first on Pharmaceutical Business review....

The PRV was awarded after the US Food and Drug Administration (FDA) granted accelerated approval for the Kresladi (marnetegragene autotemcel) gene therapy. Kresladi comprises the patient's own haematopoietic stem cells that The post Rocket to sell PRV for $180m to advance gene therapy pipeline appeared first on Pharmaceutical Business review....

The deal was originally announced in December 2025. With the acquisition, BioMarin adds two new treatments for lysosomal storage diseases, Galafold (migalastat) for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) + The post BioMarin acquires Amicus Therapeutics for $4.8bn appeared first on Pharmaceutical Business review....

The approval allows adults with SLE on standard therapy to inject Saphnelo themselves. It is supported by results from the Phase III TULIP-SC trial, which demonstrated that subcutaneous The post FDA approves AstraZeneca's Saphnelo for SLE appeared first on Pharmaceutical Business review....

The European Commission (EC) has approved Novartis' Rhapsido (remibrutinib) for certain CSU patients, becoming the first oral treatment for the skin disease. Rhapsido is approved for adult CSU The post Novartis secures pair of regulatory wins for skin disease and malaria treatments appeared first on Pharmaceutical Business review....

Organon, created through a spinoff from Merck & Co (MSD) in 2021, distributes more than 70 products across women's health and general medicines, including biosimilars, reaching 140 countries. The post Sun Pharma to acquire Organon for $11.75bn appeared first on Pharmaceutical Business review....

The initiative aims to link external scientific data with internal R&D planning by creating a unified system that supports decision-making, improves market forecasting, and helps prioritise strategic investments. The post OZMOSI and Planview partner to enhance pharmaceutical data integration appeared first on Pharmaceutical Business review....

Under the agreement, Apotex will acquire Cumberland's branded medicines for cash, subject to approval by Cumberland's shareholders. The partnership aims to establish a robust platform for speciality medicines The post Cumberland to sell drug portfolio to Apotex for $100m appeared first on Pharmaceutical Business review....

The approval expands the previous indication from those aged eight and above and was granted under a priority review process. This decision is supported by one-year data from The post Sanofi receives FDA approval for Tzield in paediatric diabetes appeared first on Pharmaceutical Business review....

The collaboration aims to implement an agentic platform across MSD's research and development (R&D), commercial, manufacturing and corporate divisions, with Google Cloud engineers working directly with MSD teams The post MSD teams up with Google Cloud on agentic AI transformation appeared first on Pharmaceutical Business review....

The approval covers Bosaya in a 60mg/ml prefilled syringe and Vevzuo in a 120mg/1.7ml (70mg/ml) single-dose vial, both for subcutaneous injection. Denosumab therapies are used to increase bone The post Health Canada approves Biocon's two denosumab biosimilars appeared first on Pharmaceutical Business review....

The collaboration will evaluate biomarkers and patient subgroups with improved responses to BioAegis' gelsolin therapy, a critical immune regulatory protein that aims to rebalance inflammation without suppressing immune The post BioAegis and Prenosis partner for inflammatory disease therapies appeared first on Pharmaceutical Business review....

The application aims to allow the use of this combination therapy for all patients with MIBC, regardless of their cisplatin eligibility. It could potentially broaden the approved use, The post Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy appeared first on Pharmaceutical Business review....

The move comes after Asahi Kasei signed a definitive agreement to acquire all issued shares of Aicuris for approximately €780m ($920.7m) earlier this year. The acquisition aligns with Asahi Kasei's The post Asahi Kasei acquires German company Aicuris appeared first on Pharmaceutical Business review....

The deal value comprises an upfront payment of up to $650m and up to $500m in future milestones. Subject to customary conditions and anti-trust clearance, the transaction is The post UCB to purchase Neurona and NRTX-1001 for $1.15bn appeared first on Pharmaceutical Business review....

This approval authorises Enflonsia's marketing across all 27 European Union member states, Iceland, Liechtenstein and Norway. Enflonsia is a long-acting monoclonal antibody intended for prevention, providing protection over The post MSD secures EC approval for Enflonsia to prevent infant RSV infection appeared first on Pharmaceutical Business review....

This territory includes Hong Kong, Macau, Mainland China, and Taiwan. The focus of the partnership is to address the needs of more than 90 million people affected by The post Aligos and Xiamen Amoytop sign deal for HBV therapy appeared first on Pharmaceutical Business review....

The agreement involves Daiichi Sankyo Research Institute Boston and aims to assess the use of Interna's MNM technology as a delivery enhancer for therapeutic modalities. Interna's MNM molecules The post Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions appeared first on Pharmaceutical Business review....